NONALCOHOLIC STEATOHEPATITIS (NASH)
Clinical trials for NONALCOHOLIC STEATOHEPATITIS (NASH) explained in plain language.
Never miss a new study
Get alerted when new NONALCOHOLIC STEATOHEPATITIS (NASH) trials appear
Sign up with your email to follow new studies for NONALCOHOLIC STEATOHEPATITIS (NASH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise against fatty liver in Mid-Stage trial
Disease control OngoingThis study tests a new medicine called miricorilant in 175 adults with nonalcoholic steatohepatitis (NASH/MASH), a type of fatty liver disease that can lead to liver damage. Participants are randomly assigned to receive either the drug or a placebo, and neither they nor their doc…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE2 • Sponsor: Corcept Therapeutics • Aim: Disease control
Last updated May 17, 2026 06:16 UTC
-
New drug aimed at reversing fatty liver damage put to the test
Disease control TerminatedThis study tests a drug called Aramchol in people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. The goal is to see if Aramchol can reduce liver scarring or resolve NASH without making fibrosis worse. About 150 adults with confi…
Matched conditions: NONALCOHOLIC STEATOHEPATITIS (NASH)
Phase: PHASE3 • Sponsor: Galmed Research and Development, Ltd. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC